A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

Summary

The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia. Information on the continued efficacy of aripiprazole was also gathered in this long-term trial (until 31 Dec 2012 or until aripiprazole was otherwise available through marketed means and/or reimbursed).

Timeline

Start

1998-04

Primary completion

2012-12

Completion

2012-12

Drugs

Indications